Status:
RECRUITING
Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Schizophrenia
Eligibility:
All Genders
18-64 years
Phase:
NA
Brief Summary
This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the respon...
Detailed Description
This longitudinal mechanistic randomized controlled trial in patients with schizophrenia (SZ) and matched healthy controls (HC) examines the underlying cause of self-agency deficits in SZ and their re...
Eligibility Criteria
Inclusion
- All Subjects:
- Good general physical health
- English is first language
- No neurological disorder
- Meets MRI criteria
- No current alcohol or substance use disorder
- Schizophrenia participants:
- Schizophrenia diagnosis of any illness duration,
- Clinical stability, defined as 12 weeks outpatient status and 4 weeks low to moderate dose of antipsychotic medication (\<1000 mg. chlorpromazine equivalents), plus stable doses of all other psychotropic medications
Exclusion
- All Subjects:
- Implanted metallic parts of implanted electronic devices
- Pregnant or trying to become pregnant
- Any condition that would prevent the subject from giving voluntary informed consent
- Scalp wounds or infections
- Claustrophobia precluding MRI
- Ongoing seizures
- Neurological disorder
Key Trial Info
Start Date :
November 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04807530
Start Date
November 12 2020
End Date
December 30 2026
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF
San Francisco, California, United States, 94143